Studies suggest that SGLT-2 inhibitors may be a promising treatment for non-alcoholic fatty liver disease (NAFLD) by regulating lipid metabolism, decreasing liver fat deposits, and protecting hepatocytes from apoptosis [130]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.